Long-term outcome of stem cell transplantation with and without anti-tumor necrotic factor therapy in perianal fistula with Crohn’s disease

Table 1 Patient characteristics and clinical variables between anti-tumor necrotic factor and without anti-tumor necrotic factor groups, n (%)

	Anti-TNF (n = 27)	Without anti-TNF (n = 38)	P value
Age, median (IQR) (yr)	26 (23.00-32.00)	26 (20.00-31.25)	0.378
Sex			0.596
Male	11 (40.7)	18 (47.4)
Female	16 (59.3)	20 (52.6)
Montreal classification
Age at onset			0.772
A1 (≤ 16 yr)	5 (18.5)	6 (15.8)
A2 (17-40 yr)	22 (81.5)	32 (84.2)
A3 (≥ 41 yr)	0 (0.0)	0 (0.0)
Location			0.025
L1 (Ileum)	3 (11.1)	9 (23.7)
L2 (Colon)	0 (0.0)	6 (15.8)
L3 (Ileocolon)	24 (88.9)	23 (60.5)
Behavior			0.850
B1 (non-stricturing, non-penetrating)	17 (63.0)	26 (68.4)
B2 (stricturing)	5 (18.5)	8 (21.1)
B3 (penetrating)	5 (18.5)	4 (10.5)
Fistula type			0.915
Simple	4 (14.8)	6 (15.8)
Complex	23 (85.2)	32 (84.2)
Multiple fistula	9 (33.3)	13 (46.4)	0.941
Fistula length > 7 cm	8 (29.6)	5 (13.2)	0.102
CDAI, (mean ± SD)	101.87 ± 55.69	80.79 ± 47.47	0.111
Proctitis	10 (37.0)	12 (31.6)	0.647
Stricture	3 (11.1)	3 (7.9)	0.659
Abscess	3 (11.1)	2 (5.3)	0.383
Recto-vaginal fistula	3 (11.1)	2 (5.3)	0.383
Medical treatment
Immunomodulators	11 (40.7)	28 (73.7)	0.008
Smoking	1 (3.7)	1 (2.6)	0.217
Previous fistula OP	27 (100.0)	38 (100.0)	1.000
No. previous fistula OP, mean ± SD (times)	3.30 ± 2.55	2.45 ± 3.29	0.266
Disease duration, mean ± SD (yr)	7.15 ± 4.74	5.87 ± 5.28	0.310
Follow-up, mean ± SD (months)	70.52 ± 31.74	62.58 ± 33.31	0.338

TNF: Tumor necrotic factor; IQR: Interquartile range; CDAI: Crohn’s Disease Activity Index; OP: Operation.